Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Accuracy of Tumor Measurements by 18F-FDG PET. RSNA Annual Meeting November, 2009
2. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. RSNA Annual Meeting November, 2009
3. 18F Fluoride Ion PET-CT Predicts Painful Metastatic Bone Lesions in the Thoracolumbar Spine RSNA Annual Meeting November, 2009
4. Survival after 90Y radioembolization is predicted by dose distribution scintigraphy EANM Annual Congress October, 2009
5. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT and 18F FDG PET/CT for Detection of Skeletal Metastases. EANM Annual Congress October, 2009
6. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. EANM Annual Congress October, 2009
7. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy WRSNM Annual Meeting October, 2009
8. Efficacy of 18F-FDG PET/CT for Breast Cancer EANM Annual Congress October, 2009
9. A Novel Strategy for a Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. SNM Annual Meeting June, 2009
10. Value of 18F FDG PET/CT for the Restaging of Colorectal Cancer after Treatment with Erbitux SNM Annual Meeting June, 2009
11. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin’s Lymphoma: Clinical Experience SNM Annual Meeting June, 2009
12. 18F FDG PET/CT Evaluation of Response to Oncolytic Herpes Simplex Virus (NV 1020) Therapy in Patients with Colorectal Cancer Metastatic to the Liver SNM Annual Meeting June, 2009
13. Does a Dedicated Head/Neck PET/CT Acquisition Provide Significant Benefit over Whole Body PET/CT for Evaluating Head and Neck Cancer? RSNA Annual Meeting November, 2008
14. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients EANM Annual Congress October, 2008
15. 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience EANM Annual Congress October, 2008
16. 18F-FDG PET/CT in the Evaluation of Pediatric Sarcomas SNM Annual Meeting June, 2008
17. Can 111In-Ibritumomab Imaging Predict the Outcome of 90Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin’s Lymphoma (NHL)? SNM Annual Meeting June, 2008
18. Efficacy of an Oncolytic Herpes Simplex Virus (NV1020) in Patients with Colorectal Cancer Metastatic to Liver. ASCO Annual Meeting May, 2008
19. Imaging Characteristics and Response after Intraarterial Administration of the Oncolytic Herpes Virus NV1020 to Treat Hepatic Colorectal Metastases ASCO Annual Meeting May, 2008
20. 18F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning? ACNP Annual Meeting February, 2008
21. Sarcomas: Classification, Diagnosis, and Therapeutic Approaches with an Emphasis on the Role of 18F FDG PET/CT Northern California Chapter SNM Annual Meeting February, 2008
22. Value of 18F FDG PET/CT for the Restaging of Colorectal Cancer after Treatment with Erbitux ACNP Annual Meeting February, 2008
23. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin’s Lymphoma ACNP Annual Meeting February, 2008
24. 18F FDG PET/CT in the Management of Patients with Nasopharyngeal Carcinoma RSNA Annual Meeting November, 2007
25. 18F FDG PET/CT Evaluation of Patients with Breast Cancer. RSNA Annual Meeting November, 2007
26. 18F FDG PET/CT Evaluation of Patients with Cervical Cancer. RSNA Annual Meeting November, 2007
27. Osseous and soft tissue sarcomas: when can 18F FDG PET/CT evaluation provide useful information? EANM Annual Congress October, 2007
28. 18F FDG PET/CT in the Management of Papillary Thyroid Cancer, with an Emphasis on Thyroglobulin, TSH and Lesion SUVmax Values EANM Annual Congress October, 2007
29. Comparison of Efficacy and Toxicity of Bexxar and Zevalin in the Management of Refractory Non-Hodgkin’s Lymphoma EANM Annual Congress October, 2007
30. 18F FHBG PET Imaging of T Cell Homing in Patients with Gliomas. AMI/SMI Joint Molecular Imaging Conference September, 2007
31. 18F FDG PET/CT Evaluation of Patients with Squamous Cell Carcinoma of the Head and Neck SNM Annual Meeting June, 2007
32. 90Y-Ibritumomab (Zevalin®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. SNM Annual Meeting June, 2007
33. 18F FDG PET/CT Evaluation of Ovarian Cancer. SNM Annual Meeting June, 2007
34. 18F FDG PET/CT in Squamous Cell Carcinoma of the Head and Neck: What is the Definition of Whole-Body Scanning? SNM Annual Meeting June, 2007
35. Artifacts and Pitfalls on 18F FDG PET/CT. ARRS Annual Meeting May, 2007
36. 18F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan? ACNP Annual Meeting February, 2007
37. Sentinel Lymph Node Scintigraphy and 18F FDG PET/CT in the Management of Breast Cancer ACNP Annual Meeting February, 2007
38. 18F FDG PET/CT in the Management of Melanoma. RSNA Annual Meeting November, 2006
39. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas RSNA Annual Meeting November, 2006
40. 90Y-Ibritumomab (Zevalin) in the Management of Refractory Non-Hodgkin’s Lymphoma British Nuclear Medicine Society Autumn Meeting September, 2006
41. 18F FDG PET/CT, Breast MRI and Mammography: Can Breast Cancer Be Reliably Detected? SNM Annual Meeting June, 2006
42. A. Partial Volume Correction of PET/CT Derived SUV Values in Lung Nodules. SNM Annual Meeting June, 2006
43. 18F FDG PET/CT Detection of Thyroid Cancer. SNM Annual Meeting June, 2006
44. Renal Cell Carcinoma: Can 18F FDG PET Be a Useful Tool? SNM Annual Meeting June, 2006
45. Detection of Occult Papillary Thyroid Cancer with 18F FDG PET/CT SNM Annual Meeting June, 2006
46. Post-Ifosfamide Therapy Inflammation in Musculoskeletal and Soft-Tissue Sarcomas: Evaluation with 18F FDG PET and PET/CT SNM Annual Meeting June, 2006
47. The Role of 18F FDG PET/CT and Breast MRI in the Management of Breast Cancer. ASCO Annual Meeting June, 2006
48. Merkel Cell Carcinoma: Is There a Role for 18F FDG PET/CT? AMI Annual Conference March, 2006
49. Comparison of Mammography, Breast MRI and 18F FDG PET/CT for Breast Cancer Detection AMI Annual Conference March, 2006
50. Detection of Occult Medullary Thyroid Cancer with 18F FDG PET and PET/CT RSNA Annual Meeting November, 2005
51. The Role of 18F FDG PET and CT in Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. SNM Annual Meeting June, 2005
52. Sentinel Lymph Node Imaging and 18F FDG PET in the Staging of Melanoma SNM Annual Meeting June, 2005
53. Early Response Evaluation of Therapy with AP23573 (an mTOR inhibitor) in Sarcoma using 18F FDG PET ASCO Annual Meeting May, 2005
54. PET/CT Challenges. Conjoint Southern Pacific Society of Nuclear Medicine and Los Angeles Radiological Society Spring Meeting May, 2005
55. Does 18F FDG PET Change the Staging or Surgical Management of Anal Carcinoma? ACNP Annual Meeting January, 2005
56. Does 18F FDG PET Change the Staging or Surgical Management of Anal Carcinoma? ACNP Annual Meeting January, 2000
57. 18F Fluoride Ion PET-CT Predicts Painful Metastatic Bone Lesions in the Thoracolumbar Spine RSNA Annual Meeting January, 2000
58. Accuracy of Tumor Measurements by 18F-FDG PET. RSNA Annual Meeting January, 2000
59. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. RSNA Annual Meeting January, 2000
60. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy WRSNM Annual Meeting January, 2000
61. Efficacy of 18F-FDG PET/CT for Breast Cancer EANM Annual Congress January, 2000
62. Survival after 90Y radioembolization is predicted by dose distribution scintigraphy EANM Annual Congress January, 2000
63. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. EANM Annual Congress January, 2000
64. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT and 18F FDG PET/CT for Detection of Skeletal Metastases. EANM Annual Congress January, 2000
65. Value of 18F FDG PET/CT for the Restaging of Colorectal Cancer after Treatment with Erbitux SNM Annual Meeting January, 2000
66. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin’s Lymphoma: Clinical Experience SNM Annual Meeting January, 2000
67. 18F FDG PET/CT Evaluation of Response to Oncolytic Herpes Simplex Virus (NV 1020) Therapy in Patients with Colorectal Cancer Metastatic to the Liver SNM Annual Meeting January, 2000
68. A Novel Strategy for a Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. SNM Annual Meeting January, 2000
69. Does a Dedicated Head/Neck PET/CT Acquisition Provide Significant Benefit over Whole Body PET/CT for Evaluating Head and Neck Cancer? RSNA Annual Meeting January, 2000
70. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients EANM Annual Congress January, 2000
71. 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience EANM Annual Congress January, 2000
72. 18F-FDG PET/CT in the Evaluation of Pediatric Sarcomas SNM Annual Meeting January, 2000
73. Can 111In-Ibritumomab Imaging Predict the Outcome of 90Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin’s Lymphoma (NHL)? SNM Annual Meeting January, 2000
74. Efficacy of an Oncolytic Herpes Simplex Virus (NV1020) in Patients with Colorectal Cancer Metastatic to Liver. ASCO Annual Meeting January, 2000
75. Imaging Characteristics and Response after Intraarterial Administration of the Oncolytic Herpes Virus NV1020 to Treat Hepatic Colorectal Metastases ASCO Annual Meeting January, 2000
76. Sarcomas: Classification, Diagnosis, and Therapeutic Approaches with an Emphasis on the Role of 18F FDG PET/CT Northern California Chapter SNM Annual Meeting January, 2000
77. Value of 18F FDG PET/CT for the Restaging of Colorectal Cancer after Treatment with Erbitux ACNP Annual Meeting January, 2000
78. 18F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning? ACNP Annual Meeting January, 2000
79. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin’s Lymphoma ACNP Annual Meeting January, 2000
80. 18F FDG PET/CT Evaluation of Patients with Breast Cancer. RSNA Annual Meeting January, 2000
81. 18F FDG PET/CT in the Management of Patients with Nasopharyngeal Carcinoma RSNA Annual Meeting January, 2000
82. 18F FDG PET/CT Evaluation of Patients with Cervical Cancer. RSNA Annual Meeting January, 2000
83. Osseous and soft tissue sarcomas: when can 18F FDG PET/CT evaluation provide useful information? EANM Annual Congress January, 2000
84. 18F FDG PET/CT in the Management of Papillary Thyroid Cancer, with an Emphasis on Thyroglobulin, TSH and Lesion SUVmax Values EANM Annual Congress January, 2000
85. Comparison of Efficacy and Toxicity of Bexxar and Zevalin in the Management of Refractory Non-Hodgkin’s Lymphoma EANM Annual Congress January, 2000
86. 18F FHBG PET Imaging of T Cell Homing in Patients with Gliomas. AMI/SMI Joint Molecular Imaging Conference January, 2000
87. 18F FDG PET/CT Evaluation of Patients with Squamous Cell Carcinoma of the Head and Neck SNM Annual Meeting January, 2000
88. 90Y-Ibritumomab (Zevalin®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. SNM Annual Meeting January, 2000
89. 18F FDG PET/CT Evaluation of Ovarian Cancer. SNM Annual Meeting January, 2000
90. 18F FDG PET/CT in Squamous Cell Carcinoma of the Head and Neck: What is the Definition of Whole-Body Scanning? SNM Annual Meeting January, 2000
91. Artifacts and Pitfalls on 18F FDG PET/CT. ARRS Annual Meeting January, 2000
92. 18F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan? ACNP Annual Meeting January, 2000
93. Sentinel Lymph Node Scintigraphy and 18F FDG PET/CT in the Management of Breast Cancer ACNP Annual Meeting January, 2000
94. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas RSNA Annual Meeting January, 2000
95. 18F FDG PET/CT in the Management of Melanoma. RSNA Annual Meeting January, 2000
96. 90Y-Ibritumomab (Zevalin) in the Management of Refractory Non-Hodgkin’s Lymphoma British Nuclear Medicine Society Autumn Meeting January, 2000
97. A. Partial Volume Correction of PET/CT Derived SUV Values in Lung Nodules. SNM Annual Meeting January, 2000
98. 18F FDG PET/CT Detection of Thyroid Cancer. SNM Annual Meeting January, 2000
99. Renal Cell Carcinoma: Can 18F FDG PET Be a Useful Tool? SNM Annual Meeting January, 2000
100. Detection of Occult Papillary Thyroid Cancer with 18F FDG PET/CT SNM Annual Meeting January, 2000
101. Post-Ifosfamide Therapy Inflammation in Musculoskeletal and Soft-Tissue Sarcomas: Evaluation with 18F FDG PET and PET/CT SNM Annual Meeting January, 2000
102. 18F FDG PET/CT, Breast MRI and Mammography: Can Breast Cancer Be Reliably Detected? SNM Annual Meeting January, 2000
103. The Role of 18F FDG PET/CT and Breast MRI in the Management of Breast Cancer. ASCO Annual Meeting January, 2000
104. Comparison of Mammography, Breast MRI and 18F FDG PET/CT for Breast Cancer Detection AMI Annual Conference January, 2000
105. Merkel Cell Carcinoma: Is There a Role for 18F FDG PET/CT? AMI Annual Conference January, 2000
106. Detection of Occult Medullary Thyroid Cancer with 18F FDG PET and PET/CT RSNA Annual Meeting January, 2000
107. Sentinel Lymph Node Imaging and 18F FDG PET in the Staging of Melanoma SNM Annual Meeting January, 2000
108. The Role of 18F FDG PET and CT in Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. SNM Annual Meeting January, 2000
109. PET/CT Challenges. Conjoint Southern Pacific Society of Nuclear Medicine and Los Angeles Radiological Society Spring Meeting January, 2000
110. Early Response Evaluation of Therapy with AP23573 (an mTOR inhibitor) in Sarcoma using 18F FDG PET ASCO Annual Meeting January, 2000



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Special Session ASCO Annual Meeting 2013 June, 2013
An Integrated Approach for the Early Detection of Cancer 5th Annual Symposium on PET/CT and Molecular Imaging February, 2010
PET/CT: The Big Picture 5th Annual Symposium on PET/CT and Molecular Imaging February, 2010
MRI (Whole Body, DCE, DWI) vs PET: Is PET Still Best for Oncology? 5th Annual Symposium on PET/CT and Molecular Imaging February, 2010
Round 3: 5th Annual Symposium on PET/CT and Molecular Imaging February, 2010
Updates on PET/CT and Thyroid Cancer 5th Annual Symposium on PET/CT and Molecular Imaging February, 2010

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.